These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27581752)

  • 1. In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.
    Kayık G; Tüzün NŞ; Durdagi S
    J Biomol Struct Dyn; 2017 Oct; 35(13):2830-2852. PubMed ID: 27581752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
    Kayık G; Tüzün NŞ; Durdagi S
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):311-330. PubMed ID: 28150511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural investigation of vesnarinone at the pore domains of open and open-inactivated states of hERG1 K
    Kayık G; Tüzün NŞ; Durdagi S
    J Mol Graph Model; 2017 Oct; 77():399-412. PubMed ID: 28963955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
    Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
    J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.
    Durdagi S; Randall T; Duff HJ; Chamberlin A; Noskov SY
    BMC Pharmacol Toxicol; 2014 Mar; 15():14. PubMed ID: 24606761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
    Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
    Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives.
    Aksoydan B; Kantarcioglu I; Erol I; Salmas RE; Durdagi S
    J Mol Graph Model; 2018 Jan; 79():103-117. PubMed ID: 29156380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal action of phosphodiesterase 5 inhibitors against neurodegenerative disorders: An update review.
    Singh NK; Singh P; Varshney P; Singh A; Bhushan B
    J Biochem Mol Toxicol; 2024 Nov; 38(11):e70021. PubMed ID: 39425458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
    Zoraghi R; Francis SH; Corbin JD
    Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
    Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets.
    Bajraktari G; Burhenne J; Bugert P; Haefeli WE; Weiss J
    Biochem Pharmacol; 2017 Dec; 145():54-63. PubMed ID: 28964803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line.
    Limoncella S; Lazzaretti C; Paradiso E; D'Alessandro S; Barbagallo F; Pacifico S; Guerrini R; Tagliavini S; Trenti T; Santi D; Simoni M; Sola M; Di Rocco G; Casarini L
    Mol Cell Endocrinol; 2022 Feb; 542():111527. PubMed ID: 34875337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance.
    Waldkirch E; Uckert S; Yildirim H; Sohn M; Jonas U; Stief CG; Andersson KE; Hedlund P
    World J Urol; 2005 Dec; 23(6):405-10. PubMed ID: 16292559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
    Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
    Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
    Dustan Sarazan R; Crumb WJ; Beasley CM; Emmick JT; Ferguson KM; Strnat CA; Sausen PJ
    Eur J Pharmacol; 2004 Oct; 502(3):163-7. PubMed ID: 15476742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the binding mechanisms of PDE5 with chromeno[2,3-
    Huang X; Xu P; Cao Y; Liu L; Song G; Xu L
    RSC Adv; 2018 Aug; 8(53):30481-30490. PubMed ID: 35546827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.
    Corbin JD; Zoraghi R; Francis SH
    Cell Signal; 2009 Dec; 21(12):1768-74. PubMed ID: 19665054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
    Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
    J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
    Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
    Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux.
    Subbotina A; Ravna AW; Lysaa RA; Abagyan R; Bugno R; Sager G
    J Pharm Pharmacol; 2017 Jun; 69(6):675-683. PubMed ID: 28211580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.